Traders bought shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on weakness during trading on Thursday. $57.27 million flowed into the stock on the tick-up and $39.55 million flowed out of the stock on the tick-down, for a money net flow of $17.72 million into the stock. Of all equities tracked, Regeneron Pharmaceuticals had the 24th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($0.81) for the day and closed at $410.87

Several equities analysts have recently weighed in on the company. Vetr raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price target on the stock in a report on Tuesday, August 2nd. Canaccord Genuity reaffirmed a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird cut Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $505.00 to $448.00 in a report on Friday, August 5th. Cowen and Company reaffirmed a “hold” rating and issued a $430.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $477.00.

The company has a 50-day moving average price of $399.57 and a 200 day moving average price of $388.54. The firm has a market capitalization of $42.30 billion and a P/E ratio of 63.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the company posted $2.89 EPS. The firm’s revenue was up 21.4% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.95 EPS for the current fiscal year.

In related news, Director Arthur F. Ryan sold 1,000 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $396.64, for a total transaction of $396,640.00. Following the completion of the sale, the director now owns 40,500 shares of the company’s stock, valued at approximately $16,063,920. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Sanofi acquired 64,731 shares of the company’s stock in a transaction that occurred on Tuesday, June 14th. The shares were acquired at an average cost of $363.86 per share, with a total value of $23,553,021.66. The disclosure for this purchase can be found here.

A number of hedge funds have made changes to their positions in the stock. Schwab Charles Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 16.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 218,216 shares of the biopharmaceutical company’s stock valued at $118,463,000 after buying an additional 31,441 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,447 shares of the biopharmaceutical company’s stock valued at $74,078,000 after buying an additional 7,316 shares during the period. Trexquant Investment LP purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $2,443,000. KBC Group NV boosted its stake in Regeneron Pharmaceuticals by 13.8% in the fourth quarter. KBC Group NV now owns 14,604 shares of the biopharmaceutical company’s stock valued at $7,928,000 after buying an additional 1,767 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 1,067 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.